Breast Cancer: Ovarian Suppression Benefits High-Risk Premenopausal Patients

Recent randomized clinical trials support the advantages of ovarian function suppression added to endocrine therapy compared with standard adjuvant endocrine therapy alone in higher-risk premenopausal women with hormone-sensitive breast cancer. The findings were included in the American Society of Clinical Oncology's most recent clinical practice guideline update on the topic.

 MedPage Today

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.